2-氯-n-(2-氟苄基)乙酰胺 | 895367-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-n-(2-氟苄基)乙酰胺
• 英文名称: 2-chloro-N-(2-fluorobenzyl)acetamide
• 英文别名: 2-chloro-N-[(2-fluorophenyl)methyl]acetamide
• CAS: 895367-63-2
• 化学式: C₉H₉ClFNO
• mdl: MFCD08076774
• 分子量: 201.628
• InChiKey: XOVDAXFGBGURQF-UHFFFAOYSA-N

物化性质

• 沸点：
  367.4±32.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-氯-n-(2-氟苄基)乙酰胺 在 叠氮基三甲基硅烷 、 sodium fluoride 作用下， 以 四氢呋喃 、 水 为溶剂， 以78 %的产率得到2-azido-N-(2-fluorobenzyl)acetamide
  参考文献：
  名称：

  二次氧化膦的化学发散施陶丁格反应及其在 LL–D05139β 钾盐全合成中的应用

  摘要：

  二级氧化膦 (SPO) 史无前例的化学发散施陶丁格反应已经开发出来。已经实现了试剂控制的 1-或 2-氮原子从叠氮化物中的排除。手性SPO立体保留转化为次膦酰胺，首次合成了天然产物LL-D05139β的钾盐。

  DOI：

  10.1002/anie.202310118
• 作为产物：
  描述：

  2-氟苄胺 、 氯乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以57%的产率得到2-氯-n-(2-氟苄基)乙酰胺
  参考文献：
  名称：

  响应水中氰化物浓度变化的镧系元素络合物

  摘要：

  已显示氰离子与水溶液中的苯甲酰DO3A衍生物的镧系元素络合物相互作用，从而导致发光和NMR光谱发生变化。这些变化是氰醇形成的结果，苯甲酰基羰基与镧系元素中心的配位作用促进了氰醇的形成。这些络合物显示出对氟化物的最小亲和力，并且可以检测浓度小于1μm的氰化物。相比之下，镧系元素与DOTAM衍生物的配合物对水中的氰化物没有亲和力，但对氟化物浓度的变化有反应。

  DOI：

  10.1002/anie.201702296

文献信息

• Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor
  作者：Ramesh C. Gupta、Laxmikant Chhipa、Appaji B. Mandhare、Shitalkumar P. Zambad、Vijay Chauthaiwale、Sunil S. Nadkarni、Chaitanya Dutt

  DOI：10.1016/j.bmcl.2009.07.058

  日期：2009.9

  A novel class of N-substituted 4-hydrazino piperidine derivatives were designed, synthesized and evaluated for DPP IV inhibition. The SAR studies on the N-substituted piperidine led to the discovery of compound 22e as a potent DPP IV inhibitor (IC50 88 nM), which is highly selective over other peptidases. In vivo efficacy indicates that compound 22e stimulates insulin release in response to glucose

  设计，合成并评估了新型的N-取代的4-肼基哌啶衍生物对DPP IV的抑制作用。对N-取代哌啶的SAR研究导致发现化合物22e作为有效的DPP IV抑制剂（IC 50 88 nM），对其他肽酶具有高度选择性。体内功效表明，化合物22e可响应n5-STZ和Zucker糖尿病脂肪（ZDF）大鼠的葡萄糖负荷而刺激胰岛素释放，并改善其葡萄糖耐量。
• Synthesis and Characterization of Novel<i>N</i>-(Phenyl, Benzyl, Hetaryl)-2-([1,2,4]Triazolo[1,5-<i>c</i>]Quinazolin-2-ylthio)Acetamides by Spectral Data, Antimicrobial Activity, Molecular Docking and QSAR Studies
  作者：Lyudmyla M. Antypenko、Sergiy I. Kovalenko、Tetyana S. Los'、Oksana L. Rebec'

  DOI：10.1002/jhet.2702

  日期：2017.3

  Candida albicans. N‐(4‐Fluorophenyl)‐2‐([1,2,4]triazolo[1,5‐c]quinazolin‐2‐ylthio)acetamide 3e had the best minimum inhibition zones against S. aureus and E. faecalis and 3‐[([1,2,4]triazolo[1,5‐c]quinazolin‐2‐ylthio)acetyl]amino}benzoic acid 3k – against E. coli, still in lower concentration, than references. By the means of in silico molecular docking into the active sites of E. faecalis dihydrofolate

  持久的新颖有效的抗微生物剂进行搜索，ñ - （苯基，苄基，杂芳基）-2 - （[1,2,4]三唑并[1,5- c ^ ]喹唑啉-2-基硫基）的合成乙酰胺，评价了结构（ LC-MS，IR，1 H-NMR谱和元素分析），并研究针对的抗菌活性的金黄色葡萄球菌，粪肠球菌，产气肠杆菌，阪坂崎，绿脓杆菌，大肠杆菌，和肺炎克雷伯氏菌，和抗真菌-反对白色念珠菌。N-（4-氟苯基）-2-（[[1,2,4]三唑[1,5-c ]喹唑啉-2-基硫基）乙酰胺3e对S的最小抑制区最好。 金黄色葡萄球菌和Ë。 粪肠球菌和3 - [（[1,2,4]三唑并[1,5- c ^ ]喹唑啉-2-基硫基）乙酰基]氨基}苯甲酸3K -反对ë。 大肠杆菌的浓度仍低于参考文献。通过计算机分子对接到E的活性位点。 粪便二氢叶酸还原酶和阴沟肠杆菌MyrA，建议可能的活动机制。计算了抗菌活性预测的定量构效关系模型。
• Substituted heterocyclic compounds
  申请人：——

  公开号：US20040152890A1

  公开（公告）日：2004-08-05

  Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.

  本发明涉及新型杂环衍生物，可用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常、间歇性跛行、普林兹梅特尔（变异型）心绞痛、稳定和不稳定性心绞痛、运动诱发性心绞痛、充血性心力衰竭和心肌梗塞。该化合物也可用于糖尿病的治疗。
• Novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides: synthesis, cytotoxicity, anticancer activity, COMPARE analysis and docking
  作者：Sergey I. Kovalenko、Inna S. Nosulenko、Alexey Yu. Voskoboynik、Galina G. Berest、Lyudmila N. Antipenko、Alexey N. Antipenko、Andrey M. Katsev

  DOI：10.1007/s00044-012-0257-x

  日期：2013.6

  The series of novel N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides were obtained by aminolysis of activated acids 1a-1d and by alkylation of potassium salts 2a-2d by N -aryl-2-chloroacetamies. The structures of compounds were determined by IR, H-1, C-13 NMR, LC- and EI-MS analyses. The results of cytotoxicity evaluation by bioluminescence inhibition of bacterium Photobacterium leiognathi Sh1 showed that compounds reveal moderate cytotoxicity. Screening of anticancer activity in vitro yielded the most active compounds 3t, 4b, 4f, 4l and 4n in micromolar concentrations with the GI(50) level (logGI(50) is from -7.57 to -4.05 for different cell lines, and logGI(50) mean graph midpoint varied from -5.30 to -4.50). Moreover, compound 4b had a distinctive selectivity against renal cancer, 4f-colon cancer and melanoma and 4l-renal cancer. The highest sensitivity to compound 4b showed renal cancer cell lines A498 (logGI(50) = -7.57). SAR-analysis was discussed, COMPARE analysis and docking was studied.The novel synthesis methods of the N-aryl(alkaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides are proposed. Anticancer activity and Photobacterium leiognathi Sh1 bioluminescence inhibition of synthesized compounds are discussed. SAR-analysis was discussed, and COMPARE analysis and docking was studied.
• Probing Structural Requirements of Positive Allosteric Modulators of the M₄ Muscarinic Receptor
  作者：Tracey Huynh、Celine Valant、Ian T. Crosby、Patrick M. Sexton、Arthur Christopoulos、Ben Capuano

  DOI：10.1021/jm401032k

  日期：2013.10.24

  The M, mAChR is implicated in several CNS disorders and possesses an allosteric binding site for which ligands modulating the affinity and/or efficacy of ACh may be exploited for selective receptor targeting. We report the synthesis of a focused library of putative M-4 PAMs derived from VU0152100 and VU10005. These compounds investigate the pharmacological effects of previously identified methoxy and fluoro substituents, providing useful estimates of affinity (K-B), cooperativity (alpha beta), and direct agonist properties (tau(B)).